Potential effectiveness and safety of olanzapine in refractory panic disorder

Michael Hollifield, Peter M. Thompson, James E. Ruiz, E. H. Uhlenhuth

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Panic disorder is a common and disabling psychiatric disorder. Despite treatment advances, refractory panic disorder requires novel interventions. One such pharmacologic intervention with theoretical and case study support includes olanzapine, a thienobenzodiazepine medication currently approved for schizophrenia in the United States. Ten people with refractory DSM-IV diagnosed panic disorder completed an 8-week, open-label, flexible-dose clinical trial. Baseline, in-treatment, and end-of-treatment data for panic attacks, anticipatory anxiety, phobic avoidance, and impairment were collected. Data were analyzed using SPSS software. Refractory panic disorder patients required a wide dose range averaging 12.3 mg/day of olanzapine to significantly improve or ablate panic attacks. On the average, number of attacks decreased from 6.1/week at baseline to 1.1/week at the end of treatment, and anticipatory anxiety from 32% of the day to 8% of the day. At treatment end, 5 of 10 participants (50%) were panic free, 4 (40%) had one attack in the previous week, 1 (10%) had seven attacks in the previous week, and 6 of 10 participants (60%) were anticipatory anxiety free. There were also statistically and clinically significant improvements in impairment over the course of the trial. There were no significant changes in vital signs, emergent side effects, or average weight, although 6 of 10 people did gain weight. Olanzapine is potentially effective and safe in panic disorder. Due to study limitations, further clinical trials are needed to demonstrate effectiveness.

Original languageEnglish (US)
Pages (from-to)33-40
Number of pages8
JournalDepression and Anxiety
Volume21
Issue number1
DOIs
StatePublished - 2005

Fingerprint

olanzapine
Panic Disorder
Safety
Anxiety
Clinical Trials
Therapeutics
Panic
Vital Signs
Diagnostic and Statistical Manual of Mental Disorders
Weight Gain
Psychiatry
Schizophrenia
Theoretical Models
Software

Keywords

  • Anxiety
  • Clinical trial
  • Olanzapine
  • Panic disorder
  • Psychopharmacology

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Psychology(all)
  • Clinical Psychology

Cite this

Hollifield, M., Thompson, P. M., Ruiz, J. E., & Uhlenhuth, E. H. (2005). Potential effectiveness and safety of olanzapine in refractory panic disorder. Depression and Anxiety, 21(1), 33-40. https://doi.org/10.1002/da.20050

Potential effectiveness and safety of olanzapine in refractory panic disorder. / Hollifield, Michael; Thompson, Peter M.; Ruiz, James E.; Uhlenhuth, E. H.

In: Depression and Anxiety, Vol. 21, No. 1, 2005, p. 33-40.

Research output: Contribution to journalArticle

Hollifield, M, Thompson, PM, Ruiz, JE & Uhlenhuth, EH 2005, 'Potential effectiveness and safety of olanzapine in refractory panic disorder', Depression and Anxiety, vol. 21, no. 1, pp. 33-40. https://doi.org/10.1002/da.20050
Hollifield, Michael ; Thompson, Peter M. ; Ruiz, James E. ; Uhlenhuth, E. H. / Potential effectiveness and safety of olanzapine in refractory panic disorder. In: Depression and Anxiety. 2005 ; Vol. 21, No. 1. pp. 33-40.
@article{87070f13e2674ea8bd0b072f2626caea,
title = "Potential effectiveness and safety of olanzapine in refractory panic disorder",
abstract = "Panic disorder is a common and disabling psychiatric disorder. Despite treatment advances, refractory panic disorder requires novel interventions. One such pharmacologic intervention with theoretical and case study support includes olanzapine, a thienobenzodiazepine medication currently approved for schizophrenia in the United States. Ten people with refractory DSM-IV diagnosed panic disorder completed an 8-week, open-label, flexible-dose clinical trial. Baseline, in-treatment, and end-of-treatment data for panic attacks, anticipatory anxiety, phobic avoidance, and impairment were collected. Data were analyzed using SPSS software. Refractory panic disorder patients required a wide dose range averaging 12.3 mg/day of olanzapine to significantly improve or ablate panic attacks. On the average, number of attacks decreased from 6.1/week at baseline to 1.1/week at the end of treatment, and anticipatory anxiety from 32{\%} of the day to 8{\%} of the day. At treatment end, 5 of 10 participants (50{\%}) were panic free, 4 (40{\%}) had one attack in the previous week, 1 (10{\%}) had seven attacks in the previous week, and 6 of 10 participants (60{\%}) were anticipatory anxiety free. There were also statistically and clinically significant improvements in impairment over the course of the trial. There were no significant changes in vital signs, emergent side effects, or average weight, although 6 of 10 people did gain weight. Olanzapine is potentially effective and safe in panic disorder. Due to study limitations, further clinical trials are needed to demonstrate effectiveness.",
keywords = "Anxiety, Clinical trial, Olanzapine, Panic disorder, Psychopharmacology",
author = "Michael Hollifield and Thompson, {Peter M.} and Ruiz, {James E.} and Uhlenhuth, {E. H.}",
year = "2005",
doi = "10.1002/da.20050",
language = "English (US)",
volume = "21",
pages = "33--40",
journal = "Depression and Anxiety",
issn = "1091-4269",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Potential effectiveness and safety of olanzapine in refractory panic disorder

AU - Hollifield, Michael

AU - Thompson, Peter M.

AU - Ruiz, James E.

AU - Uhlenhuth, E. H.

PY - 2005

Y1 - 2005

N2 - Panic disorder is a common and disabling psychiatric disorder. Despite treatment advances, refractory panic disorder requires novel interventions. One such pharmacologic intervention with theoretical and case study support includes olanzapine, a thienobenzodiazepine medication currently approved for schizophrenia in the United States. Ten people with refractory DSM-IV diagnosed panic disorder completed an 8-week, open-label, flexible-dose clinical trial. Baseline, in-treatment, and end-of-treatment data for panic attacks, anticipatory anxiety, phobic avoidance, and impairment were collected. Data were analyzed using SPSS software. Refractory panic disorder patients required a wide dose range averaging 12.3 mg/day of olanzapine to significantly improve or ablate panic attacks. On the average, number of attacks decreased from 6.1/week at baseline to 1.1/week at the end of treatment, and anticipatory anxiety from 32% of the day to 8% of the day. At treatment end, 5 of 10 participants (50%) were panic free, 4 (40%) had one attack in the previous week, 1 (10%) had seven attacks in the previous week, and 6 of 10 participants (60%) were anticipatory anxiety free. There were also statistically and clinically significant improvements in impairment over the course of the trial. There were no significant changes in vital signs, emergent side effects, or average weight, although 6 of 10 people did gain weight. Olanzapine is potentially effective and safe in panic disorder. Due to study limitations, further clinical trials are needed to demonstrate effectiveness.

AB - Panic disorder is a common and disabling psychiatric disorder. Despite treatment advances, refractory panic disorder requires novel interventions. One such pharmacologic intervention with theoretical and case study support includes olanzapine, a thienobenzodiazepine medication currently approved for schizophrenia in the United States. Ten people with refractory DSM-IV diagnosed panic disorder completed an 8-week, open-label, flexible-dose clinical trial. Baseline, in-treatment, and end-of-treatment data for panic attacks, anticipatory anxiety, phobic avoidance, and impairment were collected. Data were analyzed using SPSS software. Refractory panic disorder patients required a wide dose range averaging 12.3 mg/day of olanzapine to significantly improve or ablate panic attacks. On the average, number of attacks decreased from 6.1/week at baseline to 1.1/week at the end of treatment, and anticipatory anxiety from 32% of the day to 8% of the day. At treatment end, 5 of 10 participants (50%) were panic free, 4 (40%) had one attack in the previous week, 1 (10%) had seven attacks in the previous week, and 6 of 10 participants (60%) were anticipatory anxiety free. There were also statistically and clinically significant improvements in impairment over the course of the trial. There were no significant changes in vital signs, emergent side effects, or average weight, although 6 of 10 people did gain weight. Olanzapine is potentially effective and safe in panic disorder. Due to study limitations, further clinical trials are needed to demonstrate effectiveness.

KW - Anxiety

KW - Clinical trial

KW - Olanzapine

KW - Panic disorder

KW - Psychopharmacology

UR - http://www.scopus.com/inward/record.url?scp=18144396514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144396514&partnerID=8YFLogxK

U2 - 10.1002/da.20050

DO - 10.1002/da.20050

M3 - Article

C2 - 15786486

AN - SCOPUS:18144396514

VL - 21

SP - 33

EP - 40

JO - Depression and Anxiety

JF - Depression and Anxiety

SN - 1091-4269

IS - 1

ER -